FPI-2265

225Ac-PSMA-I&T · Fusion Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FPI-2265, covering 2026-04-08 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]

See pricing